Literature DB >> 8618301

Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers.

A F Prestigiacomo1, T A Stamey.   

Abstract

PURPOSE: Because some patients show a surprising variation in serial serum prostate specific antigen (PSA) values, we determined the intra-individual or physiological variation in serum PSA by collecting sera 2 to 3 week apart without any prostatic manipulation.
MATERIALS AND METHODS: Because 4.0 to 10.0 ng./ml. PSA is the critical range for decision making, we asked all men with a PSA in this range to return 2 to 3 weeks later for a second measurement. Total serum PSA was determined by the Hybritech Tandem-R, automated Tosoh AIA-600 and Delfia section immunoassays. Free and complexed serum PSA was determined by the Delfia assays. Between assay variation (first blood specimen retested on a separate day with the second blood specimen) was compared to the physiological variation (first versus second blood specimens).
RESULTS: Mean coefficient of variation (95% confidence limits) was 10.5% for between assay and 23.5% for physiological evaluations. The preferred analysis of ratio difference variation provided a factor of 0.138 (between assay) and 0.298 (physiological) for 95% confidence limits. Changes in free or complexed PSA were not the cause of physiological variation.
CONCLUSIONS: The intra-individual physiological variation is 2 to 3 times the between assay variation for sera drawn 2 to 3 weeks apart with a PSA of 4 to 10 ng./ml. A serum PSA of 4.0 ng./ml. can increase to 5.2 ng./ml. (4.0 x 0.298) and still be within the physiological variability for 95% confidence limits.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618301

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

Review 1.  Complexed prostate-specific antigen improvement in detecting prostate cancer.

Authors:  K Okihara; R J Babaian
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 3.092

2.  Optimizing prostate biopsy strategies for the diagnosis of prostate cancer.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2003

Review 3.  Prostate cancer: 5. Diagnostic tools for early detection.

Authors:  P I Karakiewicz; A G Aprikian
Journal:  CMAJ       Date:  1998-11-03       Impact factor: 8.262

4.  Latest tests for prostatic neoplasia.

Authors:  W J Marshall
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

5.  Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Authors:  Anders Christensson; Laila Bruun; Thomas Björk; Angel M Cronin; Andrew J Vickers; Caroline J Savage; Hans Lilja
Journal:  BJU Int       Date:  2010-10-18       Impact factor: 5.588

6.  The relationship between prostate volume and prostate-specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program.

Authors:  John H Nichols; Stacy Loeb; E Jeffrey Metter; Luigi Ferrucci; H Ballentine Carter
Journal:  BJU Int       Date:  2011-11-17       Impact factor: 5.588

Review 7.  Reframing How Physical Activity Reduces The Incidence of Clinically-Diagnosed Cancers: Appraising Exercise-Induced Immuno-Modulation As An Integral Mechanism.

Authors:  Annabelle Emery; Sally Moore; James E Turner; John P Campbell
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

8.  Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer.

Authors:  Arash O Naghavi; Tobin J Strom; Kevin Nethers; Alex A Cruz; Nicholas B Figura; Kushagra Shrinath; Binglin Yue; Jongphil Kim; Matthew C Biagioli; Daniel C Fernandez; Randy V Heysek; Richard B Wilder
Journal:  Int J Clin Oncol       Date:  2014-09-06       Impact factor: 3.402

Review 9.  Recent advances in graphene-based nanobiosensors for salivary biomarker detection.

Authors:  Riccardo Goldoni; Marco Farronato; Stephen Thaddeus Connelly; Gianluca Martino Tartaglia; Woon-Hong Yeo
Journal:  Biosens Bioelectron       Date:  2020-10-13       Impact factor: 10.618

10.  Tumour and immune cell dynamics explain the PSA bounce after prostate cancer brachytherapy.

Authors:  Yoichiro Yamamoto; Chetan P Offord; Go Kimura; Shigehiko Kuribayashi; Hayato Takeda; Shinichi Tsuchiya; Hisashi Shimojo; Hiroyuki Kanno; Ivana Bozic; Martin A Nowak; Željko Bajzer; David Dingli
Journal:  Br J Cancer       Date:  2016-07-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.